Zobrazeno 1 - 10
of 171
pro vyhledávání: ''
Autor:
T. Jeroen N. Hiltermann, Diana C.J. Spierings, Sanne de Wit, Kiki C. Andree, Caroline van der Wauwer, Menno Tamminga, Harry J.M. Groen, Joost F. Swennenhuis, Wim Timens, Anke van den Berg, Peter M. Lansdorp, Leon W.M.M. Terstappen, Hilda van den Bos, Theo J. Klinkenberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(7)
Purpose: Tumor cells from patients with lung cancer are expelled from the primary tumor into the blood, but difficult to detect in the peripheral circulation. We studied the release of circulating tumor cells (CTCs) during surgery to test the hypothe
Autor:
Junjiong Zheng, Tianxin Lin, Shaoxu Wu, Yangfan Su, Hao Yu, Hao Liu, Yong Li, Jian Huang, Weibin Xie, Siya Shi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(22)
Purpose: To develop and validate a radiomics nomogram for the preoperative prediction of lymph node (LN) metastasis in bladder cancer. Experimental Design: A total of 118 eligible bladder cancer patients were divided into a training set (n = 80) and
Autor:
Zhenchao Tang, Jie Tian, Xiao-Yan Zhang, Lin Wang, Zhenyu Liu, Xiao-Ting Li, Ying-Shi Sun, Yan-Jie Shi, Hai-Tao Zhu, Shuo Wang
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(23)
Purpose: To develop and validate a radiomics model for evaluating pathologic complete response (pCR) to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer (LARC). Experimental Design: We enrolled 222 patients (152 in the pr
Autor:
Annette M. Molinaro, Nicholas Butowski, Nhan L. Tran, John G. Kuhn, Michael E. Berens, Jennie Taylor, Jennifer Clarke, Howard Colman, Timothy F. Cloughesy, Sara Nasser, John D. Carpten, Jeffrey M. Trent, Winnie S. Liang, Keith L. Ligon, Michael D. Prados, Sen Peng, Susan M. Chang, Joanna J. Phillips, David Craig, Patrick Y. Wen, Sara A. Byron, Mitchel S. Berger, Rebecca F. Halperin, Gerald M. Maggiora, John de Groot, Ingo K. Mellinghoff
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 2
Purpose: Glioblastoma is an aggressive and molecularly heterogeneous cancer with few effective treatment options. We hypothesized that next-generation sequencing can be used to guide treatment recommendations within a clinically acceptable time frame
Autor:
Lijun Zhang, Kirsten B. Goldberg, Sean Khozin, Daniel L. Suzman, Chana Weinstock, Shenghui Tang, Geoffrey Kim, Richard Pazdur, Sakar Wahby
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(16)
On October 18, 2016, the FDA approved atezolizumab (TECENTRIQ; Genentech, Inc.) for treatment of patients with metastatic non–small cell lung cancer (mNSCLC) whose disease progressed during or following platinum-containing chemotherapy. Approval wa
Autor:
Ralph Zinner, Funda Meric-Bernstam, Joseph A. Ludwig, Marianna Zahurak, Jason Roszik, Nilofe A. Azad, Vivek Subbiah, Ashley O'Connor, Christian F. Meyer, Kenna R. Mills Shaw, Razelle Kurzrock
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(15)
Purpose: Pazopanib, a multireceptor tyrosine kinase inhibitor targeting primarily VEGFRs1–3, is approved for advanced soft tissue sarcoma (STS) and renal cell cancer. Downstream of VEGFR, trametinib is an FDA-approved MEK inhibitor used for melanom
Autor:
Mizuki Nishino, Anita Giobbie-Hurder, Nikhil H. Ramaiya, Patrick A. Ott, Michael Manos, Elizabeth I. Buchbinder, F. Stephen Hodi, Nancy Bailey
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(16)
Purpose: Characterize tumor burden dynamics during PD-1 inhibitor therapy and investigate the association with overall survival (OS) in advanced melanoma. Experimental Design: The study included 107 advanced melanoma patients treated with pembrolizum
Autor:
Yeul Hong Kim, Agnes Balogh, Markus Moehler, Jae Yong Cho, Jin Won Kim, Kensei Yamaguchi, Yung-Jue Bang, Teresa Sanchez, Maria Di Bartolomeo, Jaffer A. Ajani
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(19)
Purpose: Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte–associated protein-4 interactions, enhances T-cell activation and promotes tumor immunity. This phase II study evaluated the safety and efficacy of ipilimumab monotherapy
Autor:
Christy L. Osgood, Patricia Keegan, Richard Pazdur, Leah Her, Meredith K. Chuk, Lan Huang, Kun He, Marc R. Theoret
Publikováno v:
Clin Cancer Res
On January 28, 2016, the FDA approved eribulin (Halaven; Eisai Inc.) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. The approval was based on results from a single
Autor:
Zarine Patel, Mrinal M. Gounder, Naoko Takebe, Mark J. Bluth, Jennifer K. Loo, Alexander N. Shoushtari, Mark A. Dickson, Leigh Gaffney, Lee Schneider, Joseph P. Erinjeri, Cristina R. Antonescu, Ana Sjoberg, Howard Streicher, William D. Tap, Ping Chi, Li-Xuan Qin, Mary Louise Keohan, Ronald P. DeMatteo, Sandra P. D'Angelo, Richard D. Carvajal
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(12)
Purpose: A phase Ib study of dasatinib plus ipilimumab in patients with gastrointestinal stromal tumor (GIST) and other sarcomas was performed on the basis of preclinical data demonstrating that combined KIT and CTLA-4 blockade is synergistic. Experi